Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

6:31 AM ET 8-K
Shareholder Meeting Braemar Hotels & Resorts Inc. BHR

Braemar Hotels & Resorts Shareholder Meeting

Braemar Hotels & Resorts announced its slate of eight director nominees for election at the upcoming 2026 Annual Meeting of Stockholders. The slate includes seven new independent nominees and current CEO Richard J. Stockton, representing a significant board refresh for the company.

6:24 AM ET 8-K
Clinical Trial Data Climb Bio, Inc. CLYM

Climb Bio Clinical Trial Data

Climb Bio announced initial Phase 2 data from its PrisMN trial evaluating budoprutug in patients with primary membranous nephropathy (pMN), showing a 70% mean reduction in PLA2R antibody levels at Week 12 in the 200 mg cohort. Initial data from the 600 mg cohort indicated deeper B-cell depletion and greater drug exposure, supporting the ongoing evaluation of higher doses. The company also reported a case study in minimal change disease (MCD) where a patient achieved a three-year steroid-free remission following treatment.

6:17 AM ET 8-K
M&A Deal EQT Corp EQT

EQT Signs $50B M&A Deal with Range Resources Corporation

EQT Corporation has entered into a definitive agreement to acquire Range Resources Corporation in an all-stock transaction, creating a combined natural gas company with a pro forma enterprise value of over $50 billion. Range stockholders will receive 0.987 shares of EQT common stock for each share held, resulting in EQT and Range shareholders owning approximately 73% and 27% of the combined company, respectively. The deal aims to create the largest vertically integrated natural gas producer in the U.S. with significant inventory depth and expected annual synergies of $325 million.

Value
$50B
Counterparty
Range Resources Corporation

“This transaction brings together two of the highest-quality, longest-duration asset bases in North America and creates a company uniquely positioned for the next era of natural gas. As the lowest-cost natural gas producer in the industry, supported by multiple decades of high-quality inventory, the combined company will offer exceptional resilience through commodity cycles while maintaining significant upside to strengthening natural gas fundamentals.”

Toby Z. Rice, EQT President and CEO
6:13 AM ET 8-K
M&A Deal Amanat Acquisition Corp. AMAN

Amanat Acquisition Signs $377M M&A Deal with Corxel Pharmaceuticals, Inc.

Amanat Acquisition Corp (AMAN) has entered into a definitive business combination agreement with Corxel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on oral obesity therapies. The transaction is expected to provide approximately $377 million in gross proceeds, including a $300 million PIPE investment from institutional investors. Upon closing, expected in the first half of 2027, the combined company will focus on advancing Corxel's oral GLP-1 receptor agonist, CX11, into Phase 3 clinical trials.

Value
$377M
Counterparty
Corxel Pharmaceuticals, Inc.
6:11 AM ET 10-Q
Financial Results Atlantis Glory Inc. AGLY

Atlantis Glory Q3 2026 Results: Net Loss of $7.58K, Loss Narrows

Atlantis Glory Inc. remains a dormant shell company with no revenue and no assets as of September 30, 2026. The company reported a net loss of $24,377 for the nine months ended September 30, 2026, primarily due to general and administrative expenses, and is currently seeking a reverse merger.

Key figure
Net loss $7.58K
6:09 AM ET 8-K
Leadership Change Game Your Game Inc. GYGY

Game Your Game Leadership Change

Game Your Game Inc. appointed Wendy Loundermon as Chief Financial Officer, effective October 16, 2026, succeeding Dominic Poole. Ms. Loundermon previously served as CFO of Grafiti LLC and XTI Aerospace, Inc., while Mr. Poole will remain with the company as Vice President of Finance. Additionally, the company amended warrants held by Streeterville Capital, LLC to reduce their exercise price to $1.00 per share.

6:07 AM ET 8-K
Business Update Artificial Intelligence Technology Solutions Inc. AITX

Artificial Intelligence Technology Solutions Business Update

Artificial Intelligence Technology Solutions Inc. (AITX) defined four internal operating milestones to measure its progress toward breakeven, with the first milestone (monthly operating cash breakeven) targeted for January 2027. The company is implementing a cost-reduction program aimed at saving over $350,000 per month by February 2027, which includes a reduction in force of 24 positions and cuts in marketing and cloud expenses.

6:06 AM ET 8-K
Deal Termination HyOrc Corp HYOR

HyOrc Deal Termination with ONENERGY GREENPOWER EAD and ON ENERGY EOOD

HyOrc Corporation received a notice from OnEnergy purporting to terminate their March 2026 agreement regarding a waste-to-methanol project in Bulgaria following a failed joint grant application. HyOrc is formally disputing the validity of the termination, claiming the contractual conditions for such an action have not been met, and has reserved its intellectual property rights.

Counterparty
ONENERGY GREENPOWER EAD and ON ENERGY EOOD
6:03 AM ET 8-K
Other 8-K Filing Oaktree Acquisition Corp. III Life Sciences OACC

Oaktree Acquisition Corp. III Life Sciences Other 8-K Filing

Oaktree Acquisition Corp. III Life Sciences held an extraordinary general meeting where shareholders approved an amendment to extend the deadline for completing an initial business combination from October 25, 2026, to as late as May 25, 2027. Additionally, the company's Sponsor converted 4,798,758 Class B ordinary shares into Class A ordinary shares on a one-for-one basis.

Term
up to 7 months
6:03 AM ET 8-K
Capital Raise La Rosa Holdings Corp. SRTM

Stratum Holdings Capital Raise

Stratum Holdings Corp. completed an additional closing under a securities purchase agreement with an institutional investor, issuing 200 shares of Series E Convertible Preferred Stock. The transaction generated gross proceeds of $200,000 at a stated value of $1,000 per share. This follows an initial issuance of 200 shares on September 15, 2026.

Counterparty
institutional investor
6:02 AM ET 8-K
Nasdaq/NYSE Compliance Notice Elme Communities ELMES

Elme Communities Nasdaq/NYSE Compliance Notice

The New York Stock Exchange (NYSE) has commenced proceedings to delist Elme Communities' common shares and immediately suspended trading due to abnormally low selling price levels. The company does not intend to appeal the decision as it is already executing a previously approved Plan of Sale and Liquidation. Elme anticipates its shares will begin trading over-the-counter (OTC) under the symbol 'ELMES' on October 26, 2026.

Counterparty
New York Stock Exchange
6:02 AM ET 8-K
Court & Legal Update Phathom Pharmaceuticals, Inc. PHAT

Phathom Pharmaceuticals Court & Legal Update

Phathom Pharmaceuticals announced that the FDA has opened a public docket to solicit comments regarding legal challenges brought by BDR Pharmaceuticals against the FDA's decision to grant VOQUEZNA 10 years of New Chemical Entity (NCE) exclusivity. The litigation challenges the exclusivity period that currently protects VOQUEZNA through May 2032, and a second potential generic filer, Saba Ilac Sanayii Ve Ticaret AS, has also indicated intent to join the legal challenge.

Counterparty
BDR Pharmaceuticals, Intl. Pvt. Ltd.
6:02 AM ET 8-K
Clinical Trial Data ArriVent BioPharma, Inc. AVBP

ArriVent BioPharma Clinical Trial Data

ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate ARR-217 in patients with gastrointestinal cancers, reporting a 44.8% objective response rate at the 6mg/kg dose in late-line colorectal cancer patients. The study, conducted in partnership with Lepu Biopharma, showed a manageable safety profile and has advanced into Phase 1b dose optimization with further data expected in 2027.

Counterparty
Lepu Biopharma Co., Ltd.

“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy.”

Bing Yao, Ph.D., Chief Executive Officer of ArriVent

“We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study.”

Bing Yao, Ph.D., Chief Executive Officer of ArriVent
6:02 AM ET 8-K
Clinical Trial Data Eikon Therapeutics, Inc. EIKN

Eikon Therapeutics Clinical Trial Data

Eikon Therapeutics presented updated Phase 1b data from its TeLuRide-005 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for advanced NSCLC at the 2026 ESMO Congress. The trial demonstrated a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) across the pooled population, with a safety profile supportive of outpatient administration. The squamous cohort specifically showed a 72.4% ORR and 100% DCR with a median duration of response of 12.9 months.

6:01 AM ET 8-K
Capital Raise Cyber Enviro-Tech, Inc. CETI

Cyber Enviro-Tech Capital Raise

Cyber Enviro-Tech, Inc. entered into Amendment No. 2 to its existing Equity Purchase Agreement with Monroe Street Capital Partners, LP, which allows the company to sell up to $30 million of common stock. The amendment modifies the pricing mechanism for 'put notices' to be based on the end-of-day volume-weighted average price (EOD VWAP) rather than the lowest traded price, while maintaining a 15% discount factor. The company also disclosed a prior amendment that reduced the minimum put amount to facilitate easier access to the capital facility.

Counterparty
Monroe Street Capital Partners, LP
6:01 AM ET 8-K
Nasdaq/NYSE Compliance Notice Charlton Aria Acquisition Corp CHAR

Charlton Aria Acquisition Nasdaq/NYSE Compliance Notice

Charlton Aria Acquisition Corp notified Nasdaq that it failed to satisfy audit committee independence requirements due to a compensatory payment made to a firm associated with director Kyoung Tak Kim. The company regained compliance on October 22, 2026, by removing Mr. Kim from the audit committee and appointing Wang Jo Cha as his replacement.

Counterparty
Nasdaq
6:01 AM ET 8-K
Business Update Idaho Copper Corp COPR

Idaho Copper Business Update

Idaho Copper Corporation announced the filing of its Preliminary Economic Assessment (PEA) and NI 43-101 Technical Report on the Canadian SEDAR+ system. The company also indicated it intends to file a US-compliant version of the PEA (Subpart 1300 of Regulation S-K) in the near future.

6:01 AM ET 10-Q
Financial Results Ladder Capital Corp LADR

Ladder Capital Q3 2026 Results: Net Income $65.9M, Up 243.7% YoY

Ladder Capital Corp reported its third-quarter 2026 results, identifying as a large accelerated filer with 125,992,003 shares of Class A common stock outstanding as of October 16, 2026. The filing highlights significant macroeconomic and geopolitical risks, including global trade tensions, armed conflicts in the Middle East and Ukraine, and potential impacts from AI-enabled cybersecurity threats.

Key figure
Net income $65.9M · +243.7% YoY
9:34 PM ET Form 4
Insider Buying Bluerock Private Real Estate Fund BPRE

Bluerock Private Real Estate Fund President Jordan B. Ruddy Buys $25K of Stock

Jordan B. Ruddy, President, bought 2,040 shares of Bluerock Private Real Estate Fund at $12.25 a share, worth $25K in total on Oct 21, 2026. Shares held after the trade: 19,232 (+11.9%).

Value
$25K
Shares
2,040
Price
$12.25
Role
President
Holding change
+11.9%
Trade date
Oct 21, 2026
9:25 PM ET Form 4
Insider Selling Natera, Inc. NTRA

Natera Director Jonathan Sheena Sells $1.29M of Stock

Jonathan Sheena, Director, sold 3,150 shares of Natera, Inc. at $406.50 to $416.67 a share (average $410.55) in 8 transactions, worth $1.29M in total on Oct 21, 2026. Shares held after the trade: 218,164 (-0.1%).

Value
$1.29M
Shares
3,150
Average price
$410.55
Role
Director
Holding change
-0.1%
Trade date
Oct 21, 2026
8:00 PM ET Form 4
Insider Selling CrowdStrike Holdings, Inc. CRWD

CrowdStrike Holdings President and CEO George Kurtz Sells $4.76M of Stock

George Kurtz, President and CEO, sold 20,000 shares of CrowdStrike Holdings, Inc. at $229.25 to $245.34 a share (average $238.09) in 23 transactions, worth $4.76M in total between Oct 21, 2026 and Oct 22, 2026. Shares held after the trade: 7,401,504 (-0.0%).

Value
$4.76M
Shares
20,000
Average price
$238.09
Role
President and CEO
Holding change
-0.0%
Trade date
Oct 21, 2026 to Oct 22, 2026
7:36 PM ET Form 4
Insider Selling Alamar Biosciences, Inc. ALMR

Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $10.3M of Stock

Qiming Corporate GP VI Ltd., 10% Owner, sold 342,527 shares of Alamar Biosciences, Inc. at $29.00 to $30.81 a share (average $29.92) in 23 transactions, worth $10.3M in total between Oct 21, 2026 and Oct 22, 2026. Shares held after the trade: 1,789,183 (-0.1%).

Value
$10.3M
Shares
342,527
Average price
$29.92
Role
10% Owner
Holding change
-0.1%
Trade date
Oct 21, 2026 to Oct 22, 2026
7:04 PM ET Form 4
Insider Selling Vinci Compass Investments Ltd. VINP

Vinci Compass Investments Head of Global IP&S Fernando Lovisotto Sells $369K of Stock

Fernando Lovisotto, Head of Global IP&S, sold 33,110 shares of Vinci Compass Investments Ltd. at $10.95 to $11.42 a share (average $11.13) in 4 transactions, worth $369K in total between Oct 19, 2026 and Oct 22, 2026. Shares held after the trade: 889,406 (-0.6%).

Value
$369K
Shares
33,110
Average price
$11.13
Role
Head of Global IP&S
Holding change
-0.6%
Trade date
Oct 19, 2026 to Oct 22, 2026
7:03 PM ET Form 4
Insider Selling Vinci Compass Investments Ltd. VINP

Vinci Compass Investments Pres. of Finance & Operations Bruno Augusto Sacchi Zaremba Sells $480K of Stock

Bruno Augusto Sacchi Zaremba, Pres. of Finance & Operations, sold 43,075 shares of Vinci Compass Investments Ltd. at $10.96 to $11.42 a share (average $11.15) in 4 transactions, worth $480K in total between Oct 19, 2026 and Oct 22, 2026. Shares held after the trade: 935,257 (-0.8%).

Value
$480K
Shares
43,075
Average price
$11.15
Role
Pres. of Finance & Operations
Holding change
-0.8%
Trade date
Oct 19, 2026 to Oct 22, 2026
7:00 PM ET Form 4
Insider Selling Zoom Communications, Inc. ZM

Zoom Communications Insider Santiago Subotovsky Sells $427K of Stock

Santiago Subotovsky sold 4,258 shares of Zoom Communications, Inc. at $96.61 to $101.19 a share (average $100.21) in 4 transactions, worth $427K in total between Oct 15, 2026 and Oct 21, 2026. Shares held after the trade: 117,974 (-0.3%).

Value
$427K
Shares
4,258
Average price
$100.21
Holding change
-0.3%
Trade date
Oct 15, 2026 to Oct 21, 2026
7:00 PM ET Form 4
Insider Selling Zoom Communications, Inc. ZM

Zoom Communications Insider Herbert Raymond McMaster Sells $152K of Stock

Herbert Raymond McMaster sold 1,500 shares of Zoom Communications, Inc. at $101.25 a share, worth $152K in total on Oct 21, 2026. Shares held after the trade: 6,979 (-17.7%).

Value
$152K
Shares
1,500
Price
$101.25
Holding change
-17.7%
Trade date
Oct 21, 2026
6:59 PM ET Form 4
Insider Selling Zoom Communications, Inc. ZM

Zoom Communications CFO Michelle Chang Sells $1.04M of Stock

Michelle Chang, CFO, sold 10,156 shares of Zoom Communications, Inc. at $101.93 a share, worth $1.04M in total on Oct 21, 2026. Shares held after the trade: 30,282 (-25.1%).

Value
$1.04M
Shares
10,156
Price
$101.93
Role
CFO
Holding change
-25.1%
Trade date
Oct 21, 2026
6:46 PM ET Form 4
Insider Selling Charles River Laboratories International, Inc. CRL

Charles River Laboratories International CEVP, Disc & Safety Assessment Shannon M. Parisotto Sells $743K of Stock

Shannon M. Parisotto, CEVP, Disc & Safety Assessment, sold 2,156 shares of Charles River Laboratories International, Inc. at $344.41 a share, worth $743K in total on Oct 21, 2026. Shares held after the trade: 4,807 (-31.0%).

Value
$743K
Shares
2,156
Price
$344.41
Role
CEVP, Disc & Safety Assessment
Holding change
-31.0%
Trade date
Oct 21, 2026
6:45 PM ET Form 4
Insider Selling Snowflake Inc. SNOW

Snowflake Insider Benoit Dageville Sells $16.1M of Stock

Benoit Dageville sold 50,000 shares of Snowflake Inc. at $321.74 a share, worth $16.1M in total on Oct 21, 2026. Shares held after the trade: 2,301,543 (-2.1%).

Value
$16.1M
Shares
50,000
Price
$321.74
Holding change
-2.1%
Trade date
Oct 21, 2026
6:12 PM ET Form 4
Insider Buying Pimco New York Municipal Income Fund II PNI

Pimco New York Municipal Income Fund II Insider Bank of America Corp /De/ Buys $77.1K of Stock

Bank of America Corp /De/ bought 12,170 shares of Pimco New York Municipal Income Fund II at $6.33 a share, worth $77.1K in total on Oct 21, 2026. Shares held after the trade: 12,170.

Value
$77.1K
Shares
12,170
Price
$6.33
Trade date
Oct 21, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.